Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 16/20 | 0.49 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.46 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.46 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9949469 | 0.80 | FGFR3 (0.59) | FYNFGFR3FGFR1DYRK3DYRK1A | |
| SCHEMBL9949699 | 0.78 | FGFR3 (0.57) | FYNFGFR3FGFR1KDR | |
| SCHEMBL9960949 | 0.77 | FGFR3 (0.46) | FYNFGFR3FGFR1DYRK3CCNT1 | |
| SCHEMBL9949831 | 0.73 | FGFR3 (0.55) | FYNFGFR3FGFR1KDR | |
| SCHEMBL10145487 | 0.72 | TGFBR1 (0.32) | FGFR3FGFR1 | |
| SCHEMBL3323786 | 0.71 | KDR (0.76) | FGFR3KDR | |
| SCHEMBL9949705 | 0.71 | FGFR3 (0.65) | FGFR3KDR | |
| SCHEMBL9949521 | 0.70 | FGFR3 (0.52) | FYNFGFR3FGFR1DYRK3DYRK1A | |
| SCHEMBL10145502 | 0.70 | FYN (0.53) | FYNFGFR3FGFR1DYRK3CCNT1 | |
| SCHEMBL9949662 | 0.70 | FGFR3 (0.61) | FGFR3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170165263-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | INCYTE CORPORATION | 2017-06-15 | — | — | US | disclosed |
| US-9533954-B2 | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 | INCYTE CORPORATION (US) | 2017-01-03 | — | — | US | disclosed |
| US-20140243308-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | INCYTE CORPORATION (US) | 2014-08-28 | — | — | US | disclosed |
| US-8754114-B2 | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 | INCYTE CORPORATION (US) | 2014-06-17 | — | — | US | disclosed |
| US-20120165305-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | INCYTE CORPORATION | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165305-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | FGFR3, FGFR4, FGFR2 | FYN 53/4885FGFR3 1/4885FGFR1 4/4885 |
| US-20170165263-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | FGFR3, FGFR4, FGFR2 | FYN 53/4885FGFR3 1/4885FGFR1 4/4885 |
| US-20140243308-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | FGFR3, FGFR4, FGFR2 | FYN 53/4885FGFR3 1/4885FGFR1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.